Results 51 to 60 of about 253,061 (341)
Ornithine Decarboxylase mRNA is Stabilized in an mTORC1-dependent Manner in Ras-transformed Cells [PDF]
, 2012 Upon Ras activation, ODC (ornithine decarboxylase) is markedly induced, and numerous studies suggest that ODC expression is controlled by Ras effector pathways. ODC is therefore a potential target in the treatment and prevention of Ras-driven tumours. In
Albig +51 more
core +2 more sources
Unleashing rapamycin in fibrosis
Oncotarget, 2015 Rapamycin (sirolimus, rapamine) is a macrocyclic antibiotic produced by the bacteria streptomyces hygroscopicus, with immunosuppressive and antiproliferative capabilities. Rapamycin binds with FK- binding protein 12 to inhibit the mechanistic (formerly mammalian) Target of Rapamycin (mTOR) protein [1].
Alexander Gelbard, Alexander T. Hillel
openaire +3 more sources
MTOR cross-talk in cancer and potential for combination therapy [PDF]
, 2018 The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C. +7 more
core +3 more sources
The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy
Renal Failure, 2019 Background: The pathogenesis of the development of IgA nephropathy has not been clear up to now. At present, some studies revealed that the mTOR pathway may participate in IgA nephropathy; however, the mechanism has not been systematically studied.
Ning Guo +7 more
doaj +1 more source
Frontiers in Physiology, 2018 Background: Dementia has a significant impact on quality of life of older individuals. Impaired proteostasis has been implicated as a potential cause of dementia, that can be therapeutically targeted to improve patient outcomes.
Daniel S. Heard +5 more
doaj +1 more source
Frontiers in Oncology, 2021 PurposeOverexpression of breast cancer (BCa) resistance protein (BCRP) is detected in approximately 30% of BCa cases. BCRP indicates a poor response to chemotherapy, and it has become a classic target to overcome drug-resistant tumor cells. In this study,
Jing Zhang +18 more
doaj +1 more source
Investigating the effect of target of rapamycin kinase inhibition on the Chlamydomonas reinhardtii phosphoproteome: from known homologs to new targets [PDF]
, 2019 Recuperado de: https://www.biorxiv.org/content/10.1101/310102v1Target of rapamycin (TOR) kinase is a conserved regulator of cell growth whose activity is modulated in response to nutrients, energy and stress.
Couso Liáñez, Inmaculada Concepción +6 more
core +1 more source
Nutrition and Healthy Aging, 2018 David Glass and Dudley Lamming debate the question of “Is Rapamycin a Rapalog” while the world votes.
David J. Glass, Dudley W. Lamming
openaire +3 more sources
Rapamycin and Glucose-Target of Rapamycin (TOR) Protein Signaling in Plants [PDF]
Journal of Biological Chemistry, 2012 Target of rapamycin (TOR) kinase is an evolutionarily conserved master regulator that integrates energy, nutrients, growth factors, and stress signals to promote survival and growth in all eukaryotes. The reported land plant resistance to rapamycin and the embryo lethality of the Arabidopsis tor mutants have hindered functional dissection of TOR ...
Jen Sheen, Yan Xiong
openaire +3 more sources
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
FEBS Letters, EarlyView.This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley +1 more source